Main Article Content
Pneumococci, pneumonia, acute bacterial meningitis, penicillin
Background: Invasive pneumococcal disease is a significant contributor to both morbidity and mortality on a global scale. The occurrence of bacteremia in cases of pneumococcal pneumonia is an additional determinant of a poorer prognosis. However, it is essential to note that the most severe form of invasive pneumococcal infection is mainly associated with specific serotypes. The implementation of pneumococcal vaccination as a preventive measure has demonstrated a significant reduction in the occurrence of invasive pneumococcal illness among both vaccinated children and the adult population who have not received the vaccine.
Aims and objectives: The aim of this study was to evaluate and characterize the clinical characteristics of pneumococcal infections in the era of immunization.
Methods: This retrospective cohort was conducted at Dr Ziauddin Hospital from January 2018 to December 2021. 132 patients who tested positive for S-pneumo in a blood culture meeting the inclusion criteria were included in the study.
Results: The mean age of the patients was 62 years. Penicillin resistance was found in more than half of the patients. Besides penicillin, resistance was very high for ciprofloxacin, cotrimoxazole and tetracyclines. Mortality was found to be higher in elderly and dementia patients. The most common source of infection was meningitis, followed by respiratory tract infection. Penicillin use was associated with increased mortality. The need for ICU admission and pleural effusion were independent risk factors for mortality.
Conclusion; Resistance to penicillin and other antibiotics is rising. Common source of infection in this cohort was meningitis. Intensive care unit admission, low platelet count and pleural effusion are associated with increased mortality.
1. Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP) (April 04, 1997 / 46(RR-08);1-24). Accessed: https://www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm.
2. Pneumococcal vaccines. WHO position paper. Wkly Epidemiol Rec. 1999, 74:177-183.
3. Welte T, Torres A, Nathwani D: Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012, 67:71-79. 10.1136/thx.2009.129502
4. Mulholland K: Strategies for the control of pneumococcal diseases. Vaccine. 1999, 17 Suppl 1:S79-84. 10.1016/s0264-410x(99)00112-7
5. Fedson DS, Scott JA: The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine. 1999, 17 Suppl 1:S11-18. 10.1016/s0264-410x(99)00122-x
6. Honkanen PO, Mäkelä PH: Pneumococcal Vaccination in the Elderly. BioDrugs. 1999, 12:19-25. 10.2165/00063030-199912010-00003
7. Stein KE: Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992, 165 Suppl 1:S49-52. 10.1093/infdis/165-supplement_1-s49
8. Austrian R: The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med. 1976, 43:699-709.
9. Zafar A, Hasan R, Nizamuddin S, et al.: Antibiotic susceptibility in Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the Survey of Antibiotic Resistance (SOAR) 2002-15. J Antimicrob Chemother. 2016, 71 Suppl 1:i103-109. 10.1093/jac/dkw076
10. Lee DG, Kim SH, Kim SY, et al.: Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med. 2011, 26:220-252. 10.3904/kjim.2011.26.2.220
11. Varon E, Mainardi J, Gutmann L: Streptococcus pneumoniae: still a major pathogen. Clinical Microbiology and Infection. 2010, 16:401.
12. Blasi F, Mantero M, Santus P, Tarsia P: Understanding the burden of pneumococcal disease in adults. Clinical Microbiology and Infection. 2012, 18:7-14.
13. Sanz Herrero F, Lloret Perez T, Blanquer Olivas J: Bacteremic Streptococcus pneumoniae in community-acquired pneumonia: an update. Current Respiratory Medicine Reviews. 2010, 6:188-193.
14. Doern GV, Richter SS, Miller A, et al.: Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clinical infectious diseases. 2005, 41:139-148.
15. Mufson MA, Stanek RJ: Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997. The American journal of medicine. 1999, 107:34-43.
16. Bhatti JM, Raza SA, Alam AF, et al.: Antibiotic choices among healthcare professionals for enterococcal bacteremia with patterns of resistance and risk factors of mortality, in settings of poor antibiotic stewardship program — a five-year retrospective cohort study. BMC Infectious Diseases. 2023, 23:514. 10.1186/s12879-023-08498-0
17. Metlay JP: Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infectious Disease Clinics. 2004, 18:777-790.
18. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM: The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clinical infectious diseases. 2006, 42:788-797.
19. Ramirez JA, Bordon J: Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 2001, 161:848-850. 10.1001/archinte.161.6.848
20. Sun HK, Nicolau DP, Kuti JL: Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest. 2006, 130:807-814. 10.1378/chest.130.3.807
21. Peralta G, Rodríguez-Lera MJ, Garrido JC, Ansorena L, Roiz MP: Time to positivity in blood cultures of adults with Streptococcus pneumoniaebacteremia. BMC Infectious Diseases. 2006, 6:79. 10.1186/1471-2334-6-79
22. Huss A, Scott P, Stuck AE, Trotter C, Egger M: Efficacy of pneumococcal vaccination in adults: a meta-analysis. Cmaj. 2009, 180:48-58.
23. Moberley S, Holden J, Tatham D, Andrews R: Vaccines for preventing pneumococcal infection in adults The Cochrane Collaboration, editor Cochrane Database Syst. Rev. Chichester (UK): John Wiley & Sons, Ltd; 2008.
24. Lexau CA, Lynfield R, Danila R, et al.: Changing Epidemiology of Invasive Pneumococcal Disease Among Older Adults in the Era of Pediatric Pneumococcal Conjugate Vaccine. JAMA. 2005, 294:2043-2051. 10.1001/jama.294.16.2043
25. Martens P, Worm SW, Lundgren B, Konradsen HB, Benfield T: Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC infectious diseases. 2004, 4:1-7.
26. Mufson MA, Kruss DM, Wasil RE, Metzger WI: Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Archives of internal medicine. 1974, 134:505-510.
27. Rubins JB, Janoff EN: Pneumococcal Disease in the Elderly. Drugs & Aging. 2001, 18:305-311. 10.2165/00002512-200118050-00001
28. Rubins JB, Alter M, Loch J, Janoff EN: Determination of Antibody Responses of Elderly Adults to All 23 Capsular Polysaccharides after Pneumococcal Vaccination. Infection and Immunity. 1999, 67:5979-5984. doi:10.1128/iai.67.11.5979-5984.1999
29. Chan T, Tay MZ, Kyaw WM, Chow A, Ho HJ: Epidemiology, vaccine effectiveness, and risk factors for mortality for pneumococcal disease among hospitalised adults in Singapore: a case-control study. BMC Infectious Diseases. 2020, 20:423. 10.1186/s12879-020-05140-1
30. Bello S, Menéndez R, Antoni T, et al.: Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest. 2014, 146:1029-1037. 10.1378/chest.13-2853